Serum adiponectin predicts cardiovascular fitness in none-trained men

Paper Details

Research Paper 01/02/2011
Views (364) Download (11)
current_issue_feature_image
publication_file

Serum adiponectin predicts cardiovascular fitness in none-trained men

Eizadi Mojtaba , Khorshidi Davood, Dooaly Hussein, Samarikhalaj Hamidreza
J. Bio. Env. Sci.1( 1), 66-77, February 2011.
Certificate: JBES 2011 [Generate Certificate]

Abstract

Accumulating evidence indicates that obesity and overweight are associated with systemic inflammation and low cardiovascular fitness. Although the pathophysiologic mechanisms of the relation between systemic inflammation and cardiovascular fitness are not fully understood. Therefore, in this study, we investigated the relationship between fasting serum adiponectin as an antiinflammatory cytokine with maximal oxygen consumption (VO2max) or heart rate as two physiological markers of cardiovascular fitness in 38 sedentary healthy adult overweight or obese men (Aged 36 to 46 years, body mass index = 30 ± 6 kg/m2). Pearson correlations were used to establish the relationship between adiponectin concentrations with other variables on obese subjects. Serum adiponectin was highly negative associated with VO2max (r=0.54, p=0.000). Serum adiponectin concentrations were also independently associated with resting heart rate in studied subjects (r = 0.52, p = 0.000). On the basis of these observational findings, it can be assumed that systemic inflammation affect cardiovascular fitness in obese human.

VIEWS 15

Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, Frittitta L. 2004. Adiponectin  Relationship  with  Lipid  Metabolism Is  Independent  of  Body  Fat  Mass:Evidence from Both Cross-Sectional and Intervention Studies 89(6), 2665-71.

Chan DC, Watts GF, Ng TW, Uchida Y, Sakai N, Yamashita S, et al. 2005. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 51, 578–85.

Chandran M, Phillips SA, Ciaraldi T, Henry RR. 2003. Adiponectin: more than just another fat cell hormone? Diabetes Care 26, 2442–50.

Fattirolli F, Cellai T, Burgisser C. 2003. Physical activity and cardiovascular health a close link]. Monaldi Arch Chest Dis 60(1), 73-8.

Fernández-Real JM, Castro A, Vázquez G, Casamitjana R, López-Bermejo A, Peñarroja G et al. 2004. Adiponectin Is Associated With Vascular Function Independent of Insulin Sensitivity. Diabetes Care 27(3), 739-45.

Galic S, Oakhill JS, Steinberg GR. 2010. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316(2), 129-39.

Gnacińska M, Małgorzewicz S, Guzek M, Lysiak-Szydłowska W, Sworczak K. 2010. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol 61(2), 160-8.

Golding LA, Meyers CR, & Sinning WE. 1989. Y’s way to physical fitness: The complete guide to fitness and instruction, 3rd Ed, Champaign, IL: Human Kinetics.

Gustafson B. 2010. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 17(4), 332-41.

Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K et al. 2006. The Relationships of Plasma Adiponectin with a Favorable Lipid Profile, Decreased Inflammation, and Less Ectopic Fat Accumulation Depend on Adiposity. Clin Chem 52(10), 1934-42.

Kondo H, Shimomura I, Matsukawa Y. 2002. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51, 2325–8.

Lakka TA, Laaksonen DE, Lakka HM, Männikkö N, Niskanen LK, Rauramaa R, Salonen JT. 2003. Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med Sci Sports Exerc 35(8), 1279-86.

Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA et al. 2002. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360, 57–8.

Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, Fu Y. 2010. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59(4), 791-9.

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8, 731–737.

McGavock JM, Anderson TJ, Lewanczuk RZ. 2006. Sedentary lifestyle and antecedents of cardiovascular disease in young adults. Am J Hypertens 19(7), 701-7.

Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ et al. 2009. Adiponectin Deficiency Increases Allergic Airway Inflammation and Pulmonary Vascular Remodeling. Am J Respir Cell Mol Biol 41(4), 397- 406.

Meilleur KG, Doumatey A, Huang H, Charles B, Chen G, Zhou J et al. 2010. Circulating adiponectin is associated with obesity and serum lipids in West Africans. J Clin Endocrinol Metab 95(7), 3517-21.

Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. 2010. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc 69(3), 324-32.

Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. 2006. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 110, 267–278.

Okamoto Y, Kihara S, Ouchi N. 2002. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767–70.

Ouchi N, Kihara S, Arita Y. 1999. Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100, 2473–6.

Peña AS, Belobrajdic DP, Wiltshire E, Gent R, Hirte C, Couper J. 2010. Adiponectin relates to smooth muscle function and folate in obese children. Int J Pediatr Obes 5(2), 185-91.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291, 1730–7.

Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K et al. 2005. Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK-and COX-2–dependent mechanisms. Nat Med 11, 1096–1103.

Shore SA, Terry RD, Flynt L. 2006. Adiponectin attenuates allergen-induced airway inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol 118, 389–95.

Shuldiner AR, Yang R, Gong DW. 2001. Resistin, obesity and insulin resistance the emerging role of the adipocyte as an endocrine organ.NEngl J Med 345,1345–1346.

Spiegelman BM, Flier JS. 2001. Obesity and the regulation of energy balance Cell 104,531–543.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM. 2001. The hormone resistin links obesity to diabetes Nature 409, 307–312.

Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–243.

Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–43.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930–1935.

Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K et al. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278, 2461–2468.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. 1994. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432.